CSF tau may flag hippocampal atrophy in new-onset refractory status epilepticus
Elevated total tau in cerebral spinal fluid may indicate initial brain injury in patients with cryptogenic new-onset refractory status epilepticus and predict subsequent hippocampal atrophy, suggest study findings.
Mixed results for tetramethylpyrazine nitrone treatment in ALS
Tetramethylpyrazine nitrone does not slow overall functional decline in patients with amyotrophic lateral sclerosis, but it may help retain grip strength and is well tolerated, suggest study findings.
Striatum microstructural damage linked to disability and cognitive impairment in ALS
Researchers have identified microstructural damage to the striatum in patients with sporadic amyotrophic lateral sclerosis that could play a key role in the motor disability and cognitive deficits associated with the condition.
Adjunctive fasudil ‘considered safe’ for amyotrophic lateral sclerosis
The Rho-associated kinase inhibitor fasudil as an adjunct to riluzole is well tolerated for the treatment of patients with amyotrophic lateral sclerosis, indicate phase 2 findings from the ROCK-ALS study.
X chromosome gene locus linked to increased AD risk
SLC9A7 on the X chromosome has been pinpointed as a novel risk locus for Alzheimer’s disease in a genetic meta-analysis of over 1.15 million individuals.
Circulating endocannabinoids potential biomarkers for ALS
Circulating endocannabinoids are associated with amyotrophic lateral sclerosis disease activity and progression, demonstrating potential prognostic value, report researchers in the European Journal of Neurology.
Blood test predicts Parkinson’s disease up to 7 years before symptom onset
Researchers have used a machine learning approach to create a panel of eight blood biomarkers that can identify people at risk for developing Parkinson’s disease up to 7 years before the first signs or symptoms.
Motor benefits for prasinezumab in rapidly progressing early-stage PD
Prasinezumab, a monoclonal antibody that binds aggregated α-synuclein, has shown promise for slowing motor progression in patients with rapidly progressing Parkinson’s disease in a post-hoc analysis of the PASADENA phase 2 study.
SMA newborn screening improves functional outcomes
Children diagnosed with spinal muscular atrophy through a newborn screening initiative have better functional outcomes than their peers diagnosed after the development of clinical symptoms, the SMARTCARE study findings show.
Lixisenatide slows motor disability progression in early PD
The glucagon-like peptide-1 receptor agonist lixisenatide slows motor disability progression in patients with early Parkinson’s disease, suggest findings from the LIXIPARK trial.
